Short answer
MYRIAD GENETICS INC (MYGN) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing contains only signature certification, not substantive Item 2.02 earnings information.
MYRIAD GENETICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only signature certification, not substantive Item 2.02 earnings information
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $190.7M, down 11% YoY; average revenue per test fell 9%, including an $11.0M prior-period collection estimate reduction
- Prenatal Health revenue declined 16% and volume 9%, offsetting Cancer Care volume growth of 6% and Mental Health volume growth of 4%
- Gross margin fell to 66.6% from 71.2%; operating loss $38.9M and adjusted net loss $23.4M versus adjusted income $4.8M
- Cash declined to $115.2M from $149.6M at December 31; Q2 adjusted free cash flow was negative $10.9M
- 2026 revenue guidance reduced to $770M-$790M; Adjusted EBITDA guidance suspended amid payer pressure and strategic efficiency review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MYRIAD GENETICS INC 8-K filings
Get the next MYGN 8-K as it lands
Follow MYGN for push alerts, or ask the research agent what this filing means.